Pathway-Based Drug Response Prediction Using Similarity Identification in Gene Expression.

ABSTRACT: Lapatinib and trastuzumab (Herceptin) are targeted therapies designed for patients with HER2+ breast tumors. Although these therapies improved survival rates of patients with this tumor type, not all the patients harboring HER2 amplification respond to these drugs. The NeoALTTO clinical trial was designed to test whether a higher response rate can be achieved by combining lapatinib and trastuzumab. Although the combination therapy showed almost double the response rate compared to the monotherapies, 40% of the patients did not respond to the treatment. In this study, we sought to identify biomarkers of HER2+ breast cancer patients' response to drugs relying on gene expression profiles of tumors. We show that univariate gene expression-based biomarkers are significant but weak predictors of

SUBMITTER: Madani Tonekaboni SA 

PROVIDER: S-EPMC7509171 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature